Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion.
Antimalarial resistance
Implementation strategies
Triple artemisinin-based combination therapy (TACT)
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
02
06
2023
accepted:
07
08
2023
medline:
8
9
2023
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
epublish
Résumé
This is a qualitative study to identify implementation challenges for deploying triple artemisinin-based combination therapy (TACT) in the Greater Mekong Subregion (GMS) of Southeast Asia and to explore strategies to overcome these challenges. In-depth interviews were conducted in three countries that have repeatedly been confronted with ACT failures: Cambodia, Vietnam, and Lao PDR. Thirty-nine key stakeholders in the healthcare systems in these countries were interviewed. One participatory workshop was conducted in Cambodia, where scenarios for potential TACT deployment were discussed. The results section is organized around four strategic themes that emerged from the data: policy support, data and evidence, logistics and operation, and downstream engagement. The study revealed that countries in the GMS currently rely on ACT to eliminate Plasmodium falciparum malaria by 2025. TACT is, however, considered to be a useful backup strategy in case of future treatment failures and to prevent the re-establishment of malaria. The study showed that a major challenge ahead is to engage decision makers and healthcare providers into deploying TACT, given the low case incidence of falciparum malaria in the GMS. Interview respondents were also skeptical whether healthcare providers would be willing to engage in new therapies for a disease they hardly encounter anymore. Hence, elaborate information dissemination strategies were considered appropriate and these strategies should especially target village malaria workers. Respondents proposed several regulatory and programmatic strategies to anticipate the formation of TACT markets in the GMS. These strategies include early dossier submission to streamline regulatory procedures, early stakeholder engagement strategies to shorten implementation timelines, and inclusion of TACT as second-line therapy to accelerate their introduction in case they are urgently needed. This paper presents a qualitative study to identify implementation challenges for deploying TACT in the GMS and to explore strategies to overcome these challenges. The findings could benefit researchers and decision makers in strategizing towards potential future deployment of TACT in the GMS to combat artemisinin and partner drug resistance.
Sections du résumé
BACKGROUND
BACKGROUND
This is a qualitative study to identify implementation challenges for deploying triple artemisinin-based combination therapy (TACT) in the Greater Mekong Subregion (GMS) of Southeast Asia and to explore strategies to overcome these challenges.
METHODS
METHODS
In-depth interviews were conducted in three countries that have repeatedly been confronted with ACT failures: Cambodia, Vietnam, and Lao PDR. Thirty-nine key stakeholders in the healthcare systems in these countries were interviewed. One participatory workshop was conducted in Cambodia, where scenarios for potential TACT deployment were discussed.
RESULTS
RESULTS
The results section is organized around four strategic themes that emerged from the data: policy support, data and evidence, logistics and operation, and downstream engagement. The study revealed that countries in the GMS currently rely on ACT to eliminate Plasmodium falciparum malaria by 2025. TACT is, however, considered to be a useful backup strategy in case of future treatment failures and to prevent the re-establishment of malaria. The study showed that a major challenge ahead is to engage decision makers and healthcare providers into deploying TACT, given the low case incidence of falciparum malaria in the GMS. Interview respondents were also skeptical whether healthcare providers would be willing to engage in new therapies for a disease they hardly encounter anymore. Hence, elaborate information dissemination strategies were considered appropriate and these strategies should especially target village malaria workers. Respondents proposed several regulatory and programmatic strategies to anticipate the formation of TACT markets in the GMS. These strategies include early dossier submission to streamline regulatory procedures, early stakeholder engagement strategies to shorten implementation timelines, and inclusion of TACT as second-line therapy to accelerate their introduction in case they are urgently needed.
CONCLUSIONS
CONCLUSIONS
This paper presents a qualitative study to identify implementation challenges for deploying TACT in the GMS and to explore strategies to overcome these challenges. The findings could benefit researchers and decision makers in strategizing towards potential future deployment of TACT in the GMS to combat artemisinin and partner drug resistance.
Identifiants
pubmed: 37674172
doi: 10.1186/s12936-023-04666-4
pii: 10.1186/s12936-023-04666-4
pmc: PMC10483751
doi:
Substances chimiques
artemisinin
9RMU91N5K2
Artemisinins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Subventions
Organisme : Foreign, Commonwealth and Development Office
ID : 300341-114
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Environ Innov Soc Transit. 2021 Sep;40:40-59
pubmed: 35106274
BMC Public Health. 2022 Apr 30;22(1):864
pubmed: 35490212
Malar J. 2013 Jun 19;12:211
pubmed: 23782869
Malar J. 2023 Jun 17;22(1):185
pubmed: 37330469
Malar J. 2016 May 20;15(1):282
pubmed: 27206729
Int Health. 2015 Jul;7(4):239-46
pubmed: 25855638
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
Malar J. 2022 Feb 22;21(1):61
pubmed: 35193586
Malar J. 2011 Aug 18;10:243
pubmed: 21851625
Curr Opin Infect Dis. 2021 Oct 1;34(5):432-439
pubmed: 34267045
Malar J. 2017 Nov 13;16(1):460
pubmed: 29132370
Lancet Infect Dis. 2022 Jun;22(6):867-878
pubmed: 35276064
Malar J. 2019 Oct 11;18(1):338
pubmed: 31581941
Glob Health Action. 2017;10(1):1271594
pubmed: 28452652
Malar J. 2017 Jul 24;16(1):296
pubmed: 28738892
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28289248
PLoS One. 2014 Apr 03;9(4):e93763
pubmed: 24699934
Malar J. 2019 Oct 3;18(1):339
pubmed: 31581951
Malar J. 2008 May 20;7:84
pubmed: 18492245
Malar J. 2017 Apr 25;16(1):173
pubmed: 28441956
Risk Manag Healthc Policy. 2011;4:89-95
pubmed: 22312231
Malar J. 2009 Oct 12;8 Suppl 1:S3
pubmed: 19818170
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7
pubmed: 18165492
Malar J. 2007 Mar 16;6:31
pubmed: 17367518
Malar J. 2016 Apr 08;15:194
pubmed: 27059952
Nat Med. 2023 Sep 21;:
pubmed: 37735560
Trans R Soc Trop Med Hyg. 2018 Jun 1;112(6):264-271
pubmed: 29917147
Malar J. 2011 Oct 31;10:326
pubmed: 22039838
PLoS Med. 2016 Mar 29;13(3):e1001984
pubmed: 27022739
Malar J. 2019 Mar 22;18(1):94
pubmed: 30902051
Health Policy Plan. 2004 Nov;19(6):356-70
pubmed: 15459161
Malar J. 2015 May 30;14:224
pubmed: 26024880
Nat Commun. 2023 Jul 29;14(1):4568
pubmed: 37516752
Acta Trop. 2012 Mar;121(3):227-39
pubmed: 21382335
PLoS One. 2021 Aug 31;16(8):e0256567
pubmed: 34464398
Malar J. 2007 May 29;6:72
pubmed: 17535417